[
    [
        {
            "time": "2021-05-12",
            "original_text": "药明康德：约334.62万股A股限售股将于5月12日解禁恢复买卖 解禁",
            "features": {
                "keywords": [
                    "药明康德",
                    "限售股",
                    "解禁"
                ],
                "sentiment_score": -0.2,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "药明康德：约334.62万股A股限售股将于5月12日解禁恢复买卖 解禁",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-05-12",
            "original_text": "药明康德：334.62万股限制性股票将于5月12日起上市流通",
            "features": {
                "keywords": [
                    "药明康德",
                    "限制性股票",
                    "上市流通"
                ],
                "sentiment_score": 0.1,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "药明康德：334.62万股限制性股票将于5月12日起上市流通",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-04-01",
            "original_text": "药明康德现1笔大宗交易 共成交480.00万元",
            "features": {
                "keywords": [
                    "药明康德",
                    "大宗交易"
                ],
                "sentiment_score": 0.0,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "药明康德现1笔大宗交易 共成交480.00万元",
                "Correlation": 8,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 4,
                "Duration": 3,
                "Entity_Density": 8,
                "Market_Scope": 2,
                "Time_Proximity": 7,
                "Headline_Structure": 5,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-Q1",
            "original_text": "药明康德2021年第一季度增速创新高",
            "features": {
                "keywords": [
                    "药明康德",
                    "第一季度",
                    "增速创新高"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "药明康德2021年第一季度增速创新高",
                "Correlation": 9,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-04-01",
            "original_text": "医药行业2020年报及2021年一季报总结：Q1业绩复苏回暖 看好CXO、疫苗、创新器械和服务等高景气板块",
            "features": {
                "keywords": [
                    "医药行业",
                    "Q1业绩复苏",
                    "CXO",
                    "疫苗",
                    "创新器械",
                    "服务"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医药行业2020年报及2021年一季报总结：Q1业绩复苏回暖 看好CXO、疫苗、创新器械和服务等高景气板块",
                "Correlation": 7,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 6,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2021-05-01",
            "original_text": "浦银国际证券给予药明康德买入评级，1Q21业绩：高速增长势头不变，CDMO业务增长强劲",
            "features": {
                "keywords": [
                    "药明康德",
                    "买入评级",
                    "CDMO业务",
                    "增长强劲"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "浦银国际证券给予药明康德买入评级，1Q21业绩：高速增长势头不变，CDMO业务增长强劲",
                "Correlation": 9,
                "Sentiment": 9,
                "Importance": 8,
                "Impact": 8,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-05-01",
            "original_text": "浙商证券维持药明康德买入评级：收入端略超预期，CDMO加速再获验证",
            "features": {
                "keywords": [
                    "药明康德",
                    "买入评级",
                    "CDMO",
                    "收入端超预期"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "浙商证券维持药明康德买入评级：收入端略超预期，CDMO加速再获验证",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-05-01",
            "original_text": "投资收益及公允价值变动收益超10亿元 药明康德一季度净利增长394.92%",
            "features": {
                "keywords": [
                    "药明康德",
                    "投资收益",
                    "公允价值变动收益",
                    "净利增长"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "投资收益及公允价值变动收益超10亿元 药明康德一季度净利增长394.92%",
                "Correlation": 10,
                "Sentiment": 10,
                "Importance": 10,
                "Impact": 10,
                "Duration": 9,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        }
    ]
]